These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 24469069)

  • 1. CXCL4L1 and CXCL4 signaling in human lymphatic and microvascular endothelial cells and activated lymphocytes: involvement of mitogen-activated protein (MAP) kinases, Src and p70S6 kinase.
    Van Raemdonck K; Gouwy M; Lepers SA; Van Damme J; Struyf S
    Angiogenesis; 2014 Jul; 17(3):631-40. PubMed ID: 24469069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiostatic and chemotactic activities of the CXC chemokine CXCL4L1 (platelet factor-4 variant) are mediated by CXCR3.
    Struyf S; Salogni L; Burdick MD; Vandercappellen J; Gouwy M; Noppen S; Proost P; Opdenakker G; Parmentier M; Gerard C; Sozzani S; Strieter RM; Van Damme J
    Blood; 2011 Jan; 117(2):480-8. PubMed ID: 20980681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platelet factor-4 variant chemokine CXCL4L1 inhibits melanoma and lung carcinoma growth and metastasis by preventing angiogenesis.
    Struyf S; Burdick MD; Peeters E; Van den Broeck K; Dillen C; Proost P; Van Damme J; Strieter RM
    Cancer Res; 2007 Jun; 67(12):5940-8. PubMed ID: 17575164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of p38(MAPK) mediates the angiostatic effect of the chemokine receptor CXCR3-B.
    Petrai I; Rombouts K; Lasagni L; Annunziato F; Cosmi L; Romanelli RG; Sagrinati C; Mazzinghi B; Pinzani M; Romagnani S; Romagnani P; Marra F
    Int J Biochem Cell Biol; 2008; 40(9):1764-74. PubMed ID: 18291705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The COOH-terminal peptide of platelet factor-4 variant (CXCL4L1/PF-4var47-70) strongly inhibits angiogenesis and suppresses B16 melanoma growth in vivo.
    Vandercappellen J; Liekens S; Bronckaers A; Noppen S; Ronsse I; Dillen C; Belleri M; Mitola S; Proost P; Presta M; Struyf S; Van Damme J
    Mol Cancer Res; 2010 Mar; 8(3):322-34. PubMed ID: 20215425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relative distribution and biological characterization of CXCL4L1 isoforms in platelets from healthy donors.
    Ruytinx P; Janssens R; Berghmans N; Gouwy M; Ronsse I; Liekens S; Proost P; Van Damme J; Struyf S
    Biochem Pharmacol; 2017 Dec; 145():123-131. PubMed ID: 28859966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stimulation of angiostatic platelet factor-4 variant (CXCL4L1/PF-4var) versus inhibition of angiogenic granulocyte chemotactic protein-2 (CXCL6/GCP-2) in normal and tumoral mesenchymal cells.
    Vandercappellen J; Noppen S; Verbeke H; Put W; Conings R; Gouwy M; Schutyser E; Proost P; Sciot R; Geboes K; Opdenakker G; Van Damme J; Struyf S
    J Leukoc Biol; 2007 Dec; 82(6):1519-30. PubMed ID: 17827342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiostatic, tumor inflammatory and anti-tumor effects of CXCL4(47-70) and CXCL4L1(47-70) in an EGF-dependent breast cancer model.
    Van Raemdonck K; Berghmans N; Vanheule V; Bugatti A; Proost P; Opdenakker G; Presta M; Van Damme J; Struyf S
    Oncotarget; 2014 Nov; 5(21):10916-33. PubMed ID: 25373734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of the CXC chemokines platelet factor-4 (CXCL4/PF-4) and its variant (CXCL4L1/PF-4var) in inflammation, angiogenesis and cancer.
    Vandercappellen J; Van Damme J; Struyf S
    Cytokine Growth Factor Rev; 2011 Feb; 22(1):1-18. PubMed ID: 21111666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CXCL4L1 inhibits angiogenesis and induces undirected endothelial cell migration without affecting endothelial cell proliferation and monocyte recruitment.
    Sarabi A; Kramp BK; Drechsler M; Hackeng TM; Soehnlein O; Weber C; Koenen RR; Von Hundelshausen P
    J Thromb Haemost; 2011 Jan; 9(1):209-19. PubMed ID: 20961394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4.
    Lasagni L; Francalanci M; Annunziato F; Lazzeri E; Giannini S; Cosmi L; Sagrinati C; Mazzinghi B; Orlando C; Maggi E; Marra F; Romagnani S; Serio M; Romagnani P
    J Exp Med; 2003 Jun; 197(11):1537-49. PubMed ID: 12782716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Platelets release CXCL4L1, a nonallelic variant of the chemokine platelet factor-4/CXCL4 and potent inhibitor of angiogenesis.
    Struyf S; Burdick MD; Proost P; Van Damme J; Strieter RM
    Circ Res; 2004 Oct; 95(9):855-7. PubMed ID: 15459074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PF-4/CXCL4 and CXCL4L1 exhibit distinct subcellular localization and a differentially regulated mechanism of secretion.
    Lasagni L; Grepin R; Mazzinghi B; Lazzeri E; Meini C; Sagrinati C; Liotta F; Frosali F; Ronconi E; Alain-Courtois N; Ballerini L; Netti GS; Maggi E; Annunziato F; Serio M; Romagnani S; Bikfalvi A; Romagnani P
    Blood; 2007 May; 109(10):4127-34. PubMed ID: 17218382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural Properties of CXCL4L1 and Its Recognition of the CXCR3 N-Terminus.
    Liu YH; Chuang CH; Lee YZ; Lee ET; Lo CL; Wu CY; Huang LK; Bikfalvi A; Sue SC
    Biochemistry; 2023 Feb; 62(3):722-734. PubMed ID: 36626574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autocrine CCL2, CXCL4, CXCL9 and CXCL10 signal in retinal endothelial cells and are enhanced in diabetic retinopathy.
    Nawaz MI; Van Raemdonck K; Mohammad G; Kangave D; Van Damme J; Abu El-Asrar AM; Struyf S
    Exp Eye Res; 2013 Apr; 109():67-76. PubMed ID: 23352833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of angiostatic platelet factor-4var/CXCL4L1 counterbalances angiogenic impulses of vascular endothelial growth factor, interleukin-8/CXCL8, and stromal cell-derived factor 1/CXCL12 in esophageal and colorectal cancer.
    Verbeke H; De Hertogh G; Li S; Vandercappellen J; Noppen S; Schutyser E; El-Asrar AA; Opdenakker G; Van Damme J; Geboes K; Struyf S
    Hum Pathol; 2010 Jul; 41(7):990-1001. PubMed ID: 20334899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oligomerization State of CXCL4 Chemokines Regulates G Protein-Coupled Receptor Activation.
    Chen YP; Wu HL; Boyé K; Pan CY; Chen YC; Pujol N; Lin CW; Chiu LY; Billottet C; Alves ID; Bikfalvi A; Sue SC
    ACS Chem Biol; 2017 Nov; 12(11):2767-2778. PubMed ID: 28945356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Src contributes to IL6-induced vascular endothelial growth factor-C expression in lymphatic endothelial cells.
    Huang YH; Yang HY; Hsu YF; Chiu PT; Ou G; Hsu MJ
    Angiogenesis; 2014 Apr; 17(2):407-18. PubMed ID: 24048742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of CXCL4/CXCR3 on the lipopolysaccharide-induced injury in human umbilical vein endothelial cells.
    Wang X; Zhao Z; Zhu K; Bao R; Meng Y; Bian J; Wan X; Yang T
    J Cell Physiol; 2019 Dec; 234(12):22378-22385. PubMed ID: 31073998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CXCR3 ligands in disease and therapy.
    Van Raemdonck K; Van den Steen PE; Liekens S; Van Damme J; Struyf S
    Cytokine Growth Factor Rev; 2015 Jun; 26(3):311-27. PubMed ID: 25498524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.